兄弟科技(002562) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 reached ¥842,485,205.62, representing a 35.69% increase year-over-year[5] - Net profit attributable to shareholders was ¥43,784,672.75, a significant increase of 282.96% compared to the same period last year[5] - The net profit after deducting non-recurring gains and losses was ¥43,051,502.53, up 527.78% year-over-year[5] - The total operating revenue for the third quarter of 2022 was CNY 2,651,745,529.19, an increase from CNY 1,905,877,936.97 in the same period last year, representing an increase of approximately 39.1%[19] - The net profit for the third quarter was CNY 274,423,057.72, a significant increase from CNY 2,981,052.25 in the same quarter of the previous year[20] - The total comprehensive income for the period was CNY 352,230,684.90, a turnaround from a loss of CNY -27,127,898.90 in the previous year[21] Assets and Liabilities - The total assets at the end of the reporting period were ¥5,826,996,839.87, reflecting a 4.03% increase from the end of the previous year[5] - The company's total assets reached CNY 5,826,996,839.87, up from CNY 5,601,478,127.75 year-over-year, indicating a growth of approximately 4.0%[18] - The total liabilities decreased to CNY 2,444,643,690.50 from CNY 2,606,145,107.85, showing a reduction of about 6.2%[18] - The company's inventory increased to CNY 872,862,834.02 from CNY 790,324,673.83, marking an increase of approximately 10.4%[17] - The total equity attributable to shareholders increased to CNY 3,382,353,149.37 from CNY 2,995,333,019.90, representing a growth of approximately 12.9%[18] Cash Flow - Cash flow from operating activities showed a net inflow of ¥196,651,683.22, a turnaround from a negative cash flow in the previous year[10] - The net cash flow from operating activities was CNY 196,651,683.22, a significant recovery from a negative cash flow of CNY -240,025,756.28 in the previous year[24] - Cash and cash equivalents increased by CNY 154,312,767.41, compared to a decrease of CNY -436,671,884.69 in the same period last year[24] - The company received CNY 115,964,300.56 in tax refunds, up from CNY 88,036,538.28 in the previous year[24] - The cash outflow from investing activities was CNY 1,500,748,110.39, compared to CNY 920,818,843.39 in the previous year, indicating increased investment activity[24] - The net cash flow from financing activities was CNY -74,963,264.36, a decrease from CNY 195,683,544.28 in the previous year, reflecting higher debt repayments[24] Shareholder Information - The total number of common shareholders at the end of the reporting period is 41,900[12] - Major shareholder Qian Zhida holds 257,395,438 shares, representing 24.22% of total shares, with 193,046,578 shares pledged[12] - Major shareholder Qian Zhiming holds 214,182,400 shares, representing 20.15% of total shares[12] - Shareholder Bai Xiaoming holds 10,081,636 shares, representing 0.95% of total shares[12] - Shareholder Qi Linrong holds 5,380,000 shares, representing 0.51% of total shares[12] Research and Development - The company’s R&D expenses increased to ¥94,807,128.65, a rise of 44.21% year-over-year, indicating a focus on innovation[9] - Research and development expenses for the quarter were CNY 94,807,128.65, compared to CNY 65,740,258.93 in the previous year, reflecting an increase of about 44.1%[20] Future Plans and Investments - The company plans to expand its production capacity for certain vitamin and chromium salt products, contributing to increased revenue[9] - The company plans to invest a total of RMB 2.5 billion in the construction of an international pharmaceutical industry base, with RMB 1.5 billion allocated for fixed assets and RMB 1 billion for R&D[15] - The company is in the process of acquiring land for the pharmaceutical project, with timelines and area subject to uncertainty[15] Compliance and Penalties - The company received an administrative penalty of RMB 19,000 for safety equipment non-compliance and has completed the necessary rectifications[15] Financial Management - The company reported a financial expense of CNY -16,041,007.84, a significant change from CNY 4,411,743.23 in the previous year, indicating improved financial management[20] - Investment income rose to ¥10,051,812.35, a 160.81% increase, attributed to higher amounts invested in financial products[9] - The company reported a basic and diluted earnings per share of CNY 0.26, compared to CNY 0.003 in the same quarter last year[21]